News

Imviva Biotech is cleared to launch a basket Phase 1b trial testing its investigational off-the-shelf CAR T-cell therapy CTA313 in progressive multiple sclerosis (MS) and other B-cell-mediated autoimmune diseases. The announcement follows the clearance of the company’s investigational new drug (IND) application by the U.S. Food and Drug…

Among people with clinically isolated syndrome (CIS) — an initial episode of symptoms suggestive of multiple sclerosis (MS) — lower levels of certain fatty molecules in the blood are associated with higher rates of future disease relapses, a new study found. Adding these metabolic features to established demographic…

A new study in mice shows that an advanced imaging technique called magnetic particle imaging, or MPI, can track exactly where therapeutic cells go after they are injected into the body. This approach could eventually help researchers and doctors study and optimize cell-based therapies for people with multiple sclerosis…

The approved injection therapy Kesimpta (ofatumumab) is generally safe and helps most adults with relapsing forms of multiple sclerosis (MS) keep their disease stable over time with few or no relapses, a real-world study has found. The data show treatment is especially effective when started at a younger…

Differences in gut bacteria may affect how people with multiple sclerosis (MS) respond to dietary interventions, according to a study. The researchers stressed that their analysis was limited to data from a small group of people, so further studies will be needed to validate and expand on the results.

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Quantum Biopharma’s application seeking clearance to begin a Phase 2 trial testing Lucid-MS in people with multiple sclerosis (MS). Quantum said the FDA requested further information before clearing the investigational new drug (IND) application and…

A new formulation of Briumvi (ublituximab) — TG Therapeutics’ therapy for relapsing forms of multiple sclerosis (MS) — designed for possible at-home self-injection was generally well tolerated and showed biological activity consistent with the approved intravenous (into-the-vein) version, according to Phase 1 trial data. The Phase 1 trial is…

First-line treatment with TG Therapeutics’ Briumvi (ublituximab) in clinical trials among people with relapsing forms of multiple sclerosis (MS) led to significantly fewer relapses, reduced signs of MRI disease activity, and better disability outcomes compared with those given the older drug Aubagio (teriflunomide) as their initial therapy.

The Multiple Sclerosis Association of America (MSAA) is expanding its patient-centered research network to include more than 1,000 people with multiple sclerosis (MS) receiving care at 20 sites across the U.S. Known as the Multiple Sclerosis Implementation Network (MSIN), the initiative brings together healthcare providers, researchers, people…

Higher consumption of ultra-processed foods, such as soft drinks, packaged snacks, and ready-to-eat meals, may be associated with an increased risk of developing multiple sclerosis (MS). That’s according to a large study involving nearly 186,000 middle-aged adults in the U.K., which found that each 10% increase in ultra-processed food intake…

A new report from the National MS Society reveals that despite major advances in treatments over the last few decades, people living with multiple sclerosis (MS) still face massive gaps in their care — particularly when it comes to managing crushing fatigue, stopping disease progression, and reversing nerve…

Kesimpta (ofatumumab) was more effective than Aubagio (teriflunomide) at suppressing disease activity in people with highly active, relapsing forms of multiple sclerosis (MS), according to new analyses from the Phase 3 ASCLEPIOS trials. After two years, those on Kesimpta were nearly 20 times more likely to achieve…

A new partnership aims to advance software that uses artificial intelligence (AI) to examine brain MRI scans for signs characteristic of multiple sclerosis (MS). Neurophet said it will work with the Vall d’Hebron Institut de Recerca (VHIR), the research institute of Vall d’Hebron University Hospital in Spain, to…

An app-based, one-to-one peer support program from Shift.ms that connects people newly diagnosed with multiple sclerosis (MS) with someone more experienced may help them feel more confident in managing their condition, with self-reported psychological benefits for both people in the pairing. That’s according to five-year data from the…

Abnormal fat buildup inside the brain’s immune cells may help to drive neurological damage and disability progression in people with progressive forms of multiple sclerosis (MS), a study found. The findings also point to a possible therapeutic target. Researchers showed that blocking an enzyme called MAGL may help reverse…

Three years of treatment with Sanofi’s investigational antibody therapy frexalimab was associated with persistently low disease activity and no new safety concerns in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from an ongoing open-label extension phase of a global Phase…

Subjective, patient-reported data on lived experiences should always be considered in the care of chronic conditions like multiple sclerosis (MS), according to a recent presentation. In a survey, many people with MS reported feeling that their lived experiences aren’t given enough consideration during visits with their care providers, and…

The understanding and management of neuropsychiatric symptoms such as depression and cognitive difficulties in multiple sclerosis (MS) have advanced substantially, but there’s more progress to be made, said Anthony Feinstein, PhD, a neuropsychiatrist and professor of psychiatry at the University of Toronto. Feinstein, who delivered the June Halper Memorial Lecture…

Advocates around the globe are coming together this Saturday, May 30, for World MS Day to push for better care, earlier diagnoses, and increased awareness for people living with multiple sclerosis (MS). Launched in 2009 by the MS International Federation (MSIF), a coalition of MS advocacy groups,…

The Consortium of Multiple Sclerosis Centers (CMSC) 2026 annual meeting kicks off today in Charlotte, North Carolina, bringing together clinicians, researchers, rehabilitation specialists, and patient advocates for three days of discussions on the latest advances in multiple sclerosis (MS) care and research. At this year’s meeting, CMSC is…

Patient enrollment is complete in a Phase 2a clinical trial testing Tiziana Life Sciences‘ foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS), a form of multiple sclerosis (MS) with limited treatment options. “Reaching full enrollment in this landmark study is a testament to the strong…

Many women with multiple sclerosis (MS) have misconceptions or a lack of information about how the disease may affect pregnancy and childbirth, and healthcare providers rarely broach the topic, a study found. The findings suggest that women with MS may be making decisions about family planning based…

The neuroprotective effects of exercise in multiple sclerosis (MS) may be aided by the irisin hormone. A study showed irisin reduced nerve cell loss and eased clinical symptoms in a mouse model of the disease, making the hormone a potential new therapeutic target. And unlike existing MS therapies…

Using psychoactive drugs such as alcohol, caffeine, nicotine, cannabis, or opioids may help ease certain symptoms of multiple sclerosis (MS) — but many of these substances can make other MS symptoms worse, a study found. The researchers also found that the specific symptoms a patient experiences significantly affect…

The two main mouse models used to study myelin damage in multiple sclerosis (MS) each replicate important but distinct biological features of the disease — but both fall short of capturing its full biological complexity, a new study shows. The findings suggest that each of these two models may…

Enrollment is half complete in an ongoing clinical study at Massachusetts General Hospital (MGH) testing whether a PET imaging tracer can reliably measure myelin damage in people with multiple sclerosis (MS). The Phase 1 study (NCT04699747) is recruiting about 60 people — healthy adults and MS patients — who…

Leaders in multiple sclerosis (MS) research and care are preparing to gather in Charlotte, North Carolina, for the Consortium of MS Centers (CMSC) annual meeting, with this year marking the organization’s 40th anniversary. Multiple Sclerosis News Today sat down with the consortium’s CEO, Kathleen Costello, to discuss the…

Tiziana Life Sciences‘ experimental nasal spray foralumab continues to show signs that it may help slow disability progression and ease fatigue in people with nonactive secondary progressive multiple sclerosis (SPMS), according to new data from an expanded access program (EAP). Fourteen people with nonactive SPMS have been using…

The presence of multiple asymptomatic spinal cord lesions — areas of damage, as captured by imaging scans — is associated with about a twofold higher risk of developing multiple sclerosis (MS) for people with a first episode of myelitis, or inflammation of the spinal cord, a new study suggests.

A 24-hour livestream to raise funds for multiple sclerosis care and research will feature musicians, comedians, and actors, including cast members from popular TV shows such as “That ’70s Show” and “Sabrina the Teenage Witch.” Comedian John Poveromo will host the…